Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders

Sleep Medicine Reviews

Volumn 18, Issue 4, 2014, Pages 333-339

  Keijzer, Henry ^a,b   Smits, Marcel G ^b,c   Duffy, Jeanne F ^d   Curfs, Leopold M G ^b,e  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c GELDERSE VALLEI HOSPITAL   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Circadian rhythm sleep disorders (CRDS); Circadian rhythms; Dim light melatonin onset (DLMO); Melatonin; Sleep; Sleep timing disorders

Indexed keywords

MELATONIN;

BIOASSAY; CHRONOTHERAPY; CIRCADIAN RHYTHM SLEEP DISORDER; DIM LIGHT MELATONIN ONSET; HUMAN; LIGHT; MASS FRAGMENTOGRAPHY; PHOTOTHERAPY; PHYSICAL PARAMETERS; POLYSOMNOGRAPHY; RADIOIMMUNOASSAY; REVIEW; SALIVA; SLEEP TIME; BLOOD; CHEMISTRY; CIRCADIAN RHYTHM; DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP DISORDERS, CIRCADIAN RHYTHM;

CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIGHT; MELATONIN; SALIVA; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 84902079593     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2013.12.001     Document Type: Review

References (90)

1. Fuller P.M., Gooley J.J., Saper C.B. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. JBiol Rhythms 2006, 21:482-493.
2. Borbely A.A. Atwo process model of sleep regulation. Hum Neurobiol 1982, 1:195-204.
3. Daan S., Beersma D.G., Borbely A.A. Timing of human sleep: recovery process gated by a circadian pacemaker. Am J Physiol 1984, 246:R161-R183.
4. Dijk D.J., Brunner D.P., Beersma D.G., Borbely A.A. Electroencephalogram power density and slow wave sleep as a function of prior waking and circadian phase. Sleep 1990, 13:430-440.
5. Dijk D.J., Czeisler C.A. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. JNeurosci 1995, 15:3526-3538.
6. Moore R.Y., Eichler V.B. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res 1972, 42:201-206.
7. Stephan F.K., Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci U S A 1972, 69:1583-1586.
8. Czeisler C.A., Duffy J.F., Shanahan T.L., Brown E.N., Mitchell J.F., Rimmer D.W., et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999, 284:2177-2181.
9. Dibner C., Schibler U., Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010, 72:517-549.
10. Lewy A.J., Wehr T.A., Goodwin F.K., Newsome D.A., Markey S.P. Light suppresses melatonin secretion in humans. Science 1980, 210:1267-1269.
11. Lewy A.J., Sack R.L., Blood M.L., Bauer V.K., Cutler N.L., Thomas K.H. Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Ciba Found Symp 1995, 183:303-317. [discussion 317-21].
12. Dagan Y. Circadian rhythm sleep disorders (CRSD). Sleep Med Rev 2002, 6:45-54.
13. American Academy of Sleep Medicine International classification of sleep disorders, revised: Diagnostic and coding manual 2001, American Academy of Sleep Medicine, Chicago, Illinois.
14. Sack R.L., Auckley D., Auger R.R., Carskadon M.A., Wright K.P., Vitiello M.V., et al. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep 2007, 30:1460-1483.
15. Sack R.L., Auckley D., Auger R.R., Carskadon M.A., Wright K.P., Vitiello M.V., et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007, 30:1484-1501.
16. Lewy A. Clinical implications of the melatonin phase response curve. JClin Endocrinol Metab 2010, 95:3158-3160.
17. Lewy A.J., Cutler N.L., Sack R.L. The endogenous melatonin profile as a marker for circadian phase position. JBiol Rhythms 1999, 14:227-236.
18. Papaioannou I., Twigg G.L., Kemp M., Roughton M., Hooper J., Morrell M.J., et al. Melatonin concentration as a marker of the circadian phase in patients with obstructive sleep apnoea. Sleep Med 2012, 13:167-171.
19. Morgenthaler T.I., Lee-Chiong T., Alessi C., Friedman L., Aurora R.N., Boehlecke B., et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007, 30:1445-1459.
20. Srinivasan V., Smits M., Spence W., Lowe A.D., Kayumov L., Pandi-Perumal S.R., et al. Melatonin in mood disorders. World J Biol Psychiatry 2006, 7:138-151.
21. van den Heuvel C.J., Lushington K. Chronobiology and insomnia: pathophysiology and treatment of circadian rhythm sleep disorders. Expert Rev Neurother 2002, 2:249-260.
22. Rahman S.A., Kayumov L., Tchmoutina E.A., Shapiro C.M. Clinical efficacy of dim light melatonin onset testing in diagnosing delayed sleep phase syndrome. Sleep Med 2009, 10:549-555.
23. Keijzer H., Smits M.G., Peeters T., Looman C.W., Endenburg S.C., Gunnewiek J.M. Evaluation of salivary melatonin measurements for dim light melatonin onset calculations in patients with possible sleep-wake rhythm disorders. Clin Chim Acta 2011, 412:1616-1620.
24. Pullman R.E., Roepke S.E., Duffy J.F. Laboratory validation of an in-home method for assessing circadian phase using dim light melatonin onset (DLMO). Sleep Med 2012, 13:703-706.
25. Wirz-Justice A., Armstrong S.M. Melatonin: nature's soporific?. JSleep Res 1996, 5:137-141.
26. Campbell S.S., Murphy P.J., van den Heuvel C.J., Roberts M.L., Stauble T.N. Etiology and treatment of intrinsic circadian rhythm sleep disorders. Sleep Med Rev 1999, 3:179-200.
27. Dodson E.R., Zee P.C. Therapeutics for circadian rhythm sleep disorders. Sleep Med Clin 2010, 5:701-715.
28. Nagtegaal J.E., Kerkhof G.A., Smits M.G., Swart A.C., Van Der Meer Y.G. Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. JSleep Res 1998, 7:135-143.
29. Burgess H.J., Revell V.L., Eastman C.I. Athree pulse phase response curve to three milligrams of melatonin in humans. JPhysiol 2008, 586:639-647.
30. Lewy A.J., Ahmed S., Jackson J.M., Sack R.L. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992, 9:380-392.
31. Mundey K., Benloucif S., Harsanyi K., Dubocovich M.L., Zee P.C. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 2005, 28:1271-1278.
32. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to melatonin and alleviation of subjective feelings of jet lag (ID 1953), and reduction of sleep onset latency, and improvement of sleep quality (ID 1953) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2010, 8:1467.
33. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2011, 9:2241.
34. KNMP Informatorium Medicamentorum 2011, The Hague.
35. Burgess H.J., Revell V.L., Molina T.A., Eastman C.I. Human phase response curves to three days of daily melatonin: 0.5mg versus 3.0mg. JClin Endocrinol Metab 2010, 95:3325-3331.
36. van Geijlswijk I.M., van der Heijden K.B., Egberts A.C., Korzilius H.P., Smits M.G. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology (Berl) 2010, 212:379-391.
37. Lewy A.J., Emens J.S., Sack R.L., Hasler B.P., Bernert R.A. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int 2002, 19:649-658.
38. Braam W., van Geijlswijk I., Keijzer H., Smits M.G., Didden R., Curfs L.M. Loss of response to melatonin treatment is associated with slow melatonin metabolism. JIntellect Disabil Res 2010, 54:547-555.
39. Lewy A.J., Sack R.L. Exogenous melatonin's phase-shifting effects on the endogenous melatonin profile in sighted humans: a brief review and critique of the literature. JBiol Rhythms 1997, 12:588-594.
40. Braam W., Keijzer H., Struijker Boudier H., Didden R., Smits M., Curfs L. CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder?. JIntellect Disabil Res 2013, 57:993-1000.
41. Braam W., Smits M.G., Didden R., Korzilius H., Van Geijlswijk I.M., Curfs L.M. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Dev Med Child Neurol 2009, 51:340-349.
42. van Geijlswijk I.M., Korzilius H.P., Smits M.G. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010, 33:1605-1614.
43. Buscemi N., Vandermeer B., Hooton N., Pandya R., Tjosvold L., Hartling L., et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006, 332:385-393.
44. van der Heijden K.B., Smits M.G., van Someren E.J., Boudewijn Gunning W. Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia. JSleep Res 2005, 14:187-194.
45. Van der Heijden K.B., Smits M.G., Van Someren E.J., Ridderinkhof K.R., Gunning W.B. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. JAm Acad Child Adolesc Psychiatry 2007, 46:233-241.
46. Arendt J., Paunier L., Sizonenko P.C. Melatonin radioimmunoassay. JClin Endocrinol Metab 1975, 40:347-350.
47. Lewy A.J., Markey S.P. Analysis of melatonin in human plasma by gas chromatography negative chemical ionization mass spectrometry. Science 1978, 201:741-743.
48. Vaughan G.M., Pelham R.W., Pang S.F., Loughlin L.L., Wilson K.M., Sandock K.L., et al. Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. JClin Endocrinol Metab 1976, 42:752-764.
49. Wetterberg L., Arendt J., Paunier L., Sizonenko P.C., Donselaar W., Heyden T. Human serum melatonin changes during the menstrual cycle. JClin Endocrinol Metab 1976, 42:185-188.
50. Wilson B.W., Snedden W., Silman R.E., Smith I., Mullen P. Agas chromatography-mass spectrometry method for the quantitative analysis of melatonin in plasma and cerebrospinal fluid. Anal Biochem 1977, 81:283-291.
51. Nagtegaal E., Peeters T., Swart W., Smits M., Kerkhof G., van der Meer G. Correlation between concentrations of melatonin in saliva and serum in patients with delayed sleep phase syndrome. Ther Drug Monit 1998, 20:181-183.
52. Voultsios A., Kennaway D.J., Dawson D. Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. JBiol Rhythms 1997, 12:457-466.
53. Yang S., Zheng X., Xu Y., Zhou X. Rapid determination of serum melatonin by ESI-MS-MS with direct sample injection. JPharm Biomed Anal 2002, 30:781-790.
54. Ma X., Chen C., Krausz K.W., Idle J.R., Gonzalez F.J. Ametabolomic perspective of melatonin metabolism in the mouse. Endocrinology 2008, 149:1869-1879.
55. Wang A.Q., Wei B.P., Zhang Y., Wang Y.J., Xu L., Lan K. An ultra-high sensitive bioanalytical method for plasma melatonin by liquid chromatography-tandem mass spectrometry using water as calibration matrix. JChromatogr B Analyt Technol Biomed Life Sci 2011, 879:2259-2264.
56. Ma X., Idle J.R., Krausz K.W., Gonzalez F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005, 33:489-494.
57. Jensen M.A., Hansen A.M., Abrahamsson P., Norgaard A.W. Development and evaluation of a liquid chromatography tandem mass spectrometry method for simultaneous determination of salivary melatonin, cortisol and testosterone. JChromatogr B Analyt Technol Biomed Life Sci 2011, 879:2527-2532.
58. Arendt J. Biochemistry of the pineal gland 1995, University Press, Cambridge.
59. De Leersnyder H., De Blois M.C., Claustrat B., Romana S., Albrecht U., Von Kleist-Retzow J.C., et al. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. JPediatr 2001, 139:111-116.
60. Potocki L., Glaze D., Tan D.X., Park S.S., Kashork C.D., Shaffer L.G., et al. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. JMed Genet 2000, 37:428-433.
61. Burgess H.J., Eastman C.I. The dim light melatonin onset following fixed and free sleep schedules. JSleep Res 2005, 14:229-237.
62. Crowley S.J., Acebo C., Fallone G., Carskadon M.A. Estimating dim light melatonin onset (DLMO) phase in adolescents using summer or school-year sleep/wake schedules. Sleep 2006, 29:1632-1641.
63. Martin S.K., Eastman C.I. Sleep logs of young adults with self-selected sleep times predict the dim light melatonin onset. Chronobiol Int 2002, 19:695-707.
64. Wright H., Lack L., Bootzin R. Relationship between dim light melatonin onset and the timing of sleep in sleep onset insomniacs. Sleep Biol Rhythms 2006, 4:78-80.
65. Cain S.W., Dennison C.F., Zeitzer J.M., Guzik A.M., Khalsa S.B., Santhi N., et al. Sex differences in phase angle of entrainment and melatonin amplitude in humans. JBiol Rhythms 2010, 25:288-296.
66. Zeitzer J.M., Duffy J.F., Lockley S.W., Dijk D.J., Czeisler C.A. Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep 2007, 30:1437-1443.
67. Bjorvatn B., Pallesen S. Apractical approach to circadian rhythm sleep disorders. Sleep Med Rev 2009, 13:47-60.
68. Molina T.A., Burgess H.J. Calculating the dim light melatonin onset: the impact of threshold and sampling rate. Chronobiol Int 2011, 28:714-718.
69. Reiter R.J., Tan D.X. What constitutes a physiological concentration of melatonin?. JPineal Res 2003, 34:79-80.
70. Benloucif S., Burgess H.J., Klerman E.B., Lewy A.J., Middleton B., Murphy P.J., et al. Measuring melatonin in humans. JClin Sleep Med 2008, 4:66-69.
71. Benloucif S., Guico M.J., Reid K.J., Wolfe L.F., L'Hermite-Baleriaux M., Zee P.C. Stability of melatonin and temperature as circadian phase markers and their relation to sleep times in humans. JBiol Rhythms 2005, 20:178-188.
72. Sack R.L., Lewy A.J., Blood M.L., Keith L.D., Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. JClin Endocrinol Metab 1992, 75:127-134.
73. Lewy A.J. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol 2007, 72:623-636.
74. Nakagawa H., Sack R.L., Lewy A.J. Sleep propensity free-runs with the temperature, melatonin and cortisol rhythms in a totally blind person. Sleep 1992, 15:330-336.
75. Lewy A.J., Newsome D.A. Different types of melatonin circadian secretory rhythms in some blind subjects. JClin Endocrinol Metab 1983, 56:1103-1107.
76. Hack L.M., Lockley S.W., Arendt J., Skene D.J. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. JBiol Rhythms 2003, 18:420-429.
77. ; 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374385.pdf.
78. Brown E.N., Czeisler C.A. The statistical analysis of circadian phase and amplitude in constant-routine core-temperature data. JBiol Rhythms 1992, 7:177-202.
79. Krauchi K., Cajochen C., Mori D., Graw P., Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997, 272:R1178-R1188.
80. Van Geijlswijk I.M., Didden R., Van der Heijden K.B., Smits M.G., Leeuwe J.F. Onset and stability of melatonin treatment effect in childhood sleep onset insomnia. Sleep Sci 2010, 3:16-21.
81. Grozinger M., Hartter S., Wang X., Roschke J., Hiemke C., Rose D.M. Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. Arch Gen Psychiatry 2000, 57:812-813.
82. Hartter S., Ursing C., Morita S., Tybring G., von Bahr C., Christensen M., et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity invivo: a pilot study. Clin Pharmacol Ther 2001, 70:10-16.
83. Levien T., Baker D. Cytochrome P450 drug interactions 2003.
84. Arendt J. Safety of melatonin in long-term use (?). JBiol Rhythms 1997, 12:673-681.
85. Garfinkel D., Zorin M., Wainstein J., Matas Z., Laudon M., Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011, 4:307-313.
86. Lemoine P., Garfinkel D., Laudon M., Nir T., Zisapel N. Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 2011, 7:301-311.
87. van Geijlswijk I.M., Mol R.H., Egberts T.C., Smits M.G. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology (Berl) 2011, 216:111-120.
88. Sanchez-Barcelo E.J., Mediavilla M.D., Tan D.X., Reiter R.J. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010, 17:2070-2095.
89. Hoebert M., van der Heijden K.B., van Geijlswijk I.M., Smits M.G. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. JPineal Res 2009, 47:1-7.
90. Skene D.J., Deacon S., Arendt J. Use of melatonin in circadian rhythm disorders and following phase shifts. Acta Neurobiol Exp (Wars) 1996, 56:359-362.